Ginkgo Bioworks Holdings, Inc. (DNA) Stock

NYSE: DNADesigns custom microbes for a variety of industries including healthcare and agriculture.

Ginkgo Bioworks stock price chart

DNA stock quote & key statistics

Ginkgo Bioworks earnings per share

Income →
Earnings per share

Ginkgo Bioworks revenue & net income

Income →
RevenueNet income

Ginkgo Bioworks annual financials

Income statement →
Ginkgo Bioworks Holdings, Inc. revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2025$170.2M-$312.8M-$5.65
FY2024$227.0M-$547.0M-$7.56
FY2023$251.5M-$892.9M-$13.54
FY2022$477.7M-$2.10B-$47.84
FY2021$313.8M-$1.83B-$4.66

Fiscal year ending December 31. Source: company filings via EODHD.

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., based in Boston, Massachusetts, is a leader in the field of cell programming technology. The company and its subsidiaries specialize in developing platforms that allow for the programming of cells, enabling them to produce a wide array of products ranging from innovative therapeutics to food ingredients and sustainable chemicals derived from petroleum. Their versatile platform serves diverse industries including specialty chemicals, agriculture, food production, consumer goods, and pharmaceuticals, contributing to advancements in bioengineering across various sectors.

In addition to their core capabilities in cell programming, Ginkgo Bioworks has established strategic collaborations to expand its technological reach and product offerings. Notably, the company has partnered with Selecta Biosciences, Inc. to advance the ImmTOR technology platform, enhancing capabilities in therapeutic development and immune modulation. These partnerships underscore Ginkgo Bioworks' commitment to leveraging cutting-edge biological engineering to address complex challenges and deliver impactful solutions.

Founded in 2008, Ginkgo Bioworks has grown into a pioneering force in biotechnology, driving innovation through its robust research and development initiatives. With its headquarters in Boston, the company continues to lead the charge in harnessing the power of biology to create sustainable and transformative products that benefit industries and society as a whole.

Ginkgo Bioworks stock FAQ

What is the Ginkgo Bioworks stock ticker symbol?

Ginkgo Bioworks Holdings, Inc. trades on the NYSE under the ticker symbol DNA.

What sector and industry is Ginkgo Bioworks in?

Ginkgo Bioworks Holdings, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Ginkgo Bioworks have?

Ginkgo Bioworks Holdings, Inc. has about 485 full-time employees.

What were Ginkgo Bioworks's revenue and earnings last fiscal year?

Ginkgo Bioworks reported revenue of $170.2M and net income of -$312.8M in fiscal 2025, with earnings per share of -$5.65. Revenue declined 25.1% from the prior year.

Is Ginkgo Bioworks in the Russell 2000?

Yes. Ginkgo Bioworks Holdings, Inc. (DNA) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Ginkgo Bioworks go public?

Ginkgo Bioworks stock began trading on April 19, 2021.

Russell 2000 Biotechnology stocks

All Russell 2000 →